Zelira Therapeutics has launched a range of CBD-based acne and skin products in the US under the brand name Raf Five.
Developed in partnership with cosmetic dermatologist Dr Karyn Grossman and drug-development chemist Dr Brian Warrington, the new line consists of five acne treatments using a proprietary formulation incorporating CBD.
Zelira’s dermatology subsidiary Ilera Derm is planning to launch other topicals in 2022 for anti-ageing, sexual health/intimacy and specific skin conditions such as psoriasis.
CEO and managing director Dr Oludare Odumosu said: “We have a unique opportunity to present a differentiated suite of proven acne treatment solutions to the US$11 billion acne treatment market where there is a high level of dissatisfaction with existing products and unmet needs.
“Zelira is staking a claim in the cannabinoid-based, over-the-counter skincare product market with our differentiated dermatology.”
Botanix Pharmaceuticals has launched a study in 45 canines with atopic dermatitis evaluating two formulations of its BTX 1204A treatment.
Positive data from a pilot study in May demonstrated that a new higher dose of synthetic CBD, in a novel Permetrex formulation, reduced the severity of atopic dermatitis over 28 days, providing strong foundations to extend the program into both animal and human health.
Botanix also provided an update on its BTX 1702 rosacea study. Despite Covid-19 restrictions in some states, recruitment is progressing according to plan in Australia and New Zealand with the team is on track to enrol 120 patients in a study investigating the safety and tolerability of two different concentrations of the drug.
Meanwhile, the company has expanded its management team with the appointment of senior vice president of pharmaceutical development, Dr Jack Hoblitzell.
Dr Hoblitzell brings more than 30 years’ experience in leading world-class technical operations, manufacturing and supply chain management.
He has held senior leadership roles in the US with companies including Pfizer, King Pharmaceuticals, Ivax Pharmaceuticals and Teva Pharmaceuticals, where he led numerous successful product launches and regulatory submissions.
Athena, a vertically integrated formulator and manufacturer of liquid and dry fertiliser designed for cannabis cultivation, has expanded into Australia.
The Athena nutrient program will be available through Australian hydroponic wholesaler Arcadia Sales Services by late October.
Athena general manager Robert Schneider said: “As we continue our efforts to supply growers around the world, we are pleased to announce the availability of Athena in Australia.
“Arcadia Sales Services will serve this market as our exclusive distributor with their track record of excellent grower support and service.”